Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of K-757 in Healthy Overweight/Obese Volunteers
NCT05900531Phase 1Completed
- Sponsor
- Kallyope
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of K757 in obesity and Overweight (6 arms), sponsored by Kallyope. Primary endpoints: Proportion of participants who experienced 1 or more treatment-emergent AEs and Proportion of participants who discontinued study medication due to an AE. Started Sep 2022; status: completed.
02
Drugs
K757
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05900531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900531.